MannKind Corp (MNKD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
62
About the Report
About the Report
Summary
MannKind Corp (MannKind) is a biopharmaceutical company that develops and commercializes inhaled therapeutic products for patients suffering from diabetes and pulmonary arterial hypertension. Its flagship product, Afrezza is a US FDA approved rapid-action inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The product consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. The company develops products based on its proprietary Technosphere formulation technology. It has manufacturing facility in Danbury, Connecticut and sells its product through wholesale distributors and specialty pharmacies. MannKind is headquartered in California, the US.
MannKind Corp (MNKD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
MannKind Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MannKind Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
MannKind Corp, Medical Devices Deals, 2012 to YTD 2018 10
MannKind Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
MannKind Corp, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
MannKind Enters into Distribution Agreement with Tanner Pharma 12
MannKind to Enter into Marketing and Distribution Agreement with Cipla 13
MannKind and Biomm Enter into Distribution Agreement 14
MannKind Partners with JDRF 15
Licensing Agreements 16
United Therapeutics Enters into Licensing Agreement with MannKind 16
Receptor Life Sciences Enters into Licensing Agreement with MannKind 17
Colby Enters Into Licensing Agreement With MannKind For Cancer Immunotherapy Products 18
MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton's Tyrosine Kinase Inhibitors 20
Equity Offering 21
MannKind Raises USD28 Million in Private Placement of Shares 21
Mannkind to Raise USD61 Million in Private Placement of Shares 23
MannKind Plans to Raise Funds through Private Placement of Shares upon Exercise of Warrants 25
MannKind Raises USD36.2 Million in Private Placement of Shares 26
Mannkind Raises USD50 Million in Private Placment of Shares 27
MannKind Announces Public Offering Of Common Stock For USD 50 Million 29
MannKind Completes Public Offering Of Common Stock And Warrants For USD 92 Million 30
MannKind Completes Public Offering Of Units For USD 86 Million 32
Debt Offering 34
MannKind Completes First Tranche Of Private Placement Of Notes For USD 40 Million 34
MannKind Corp-Key Competitors 36
MannKind Corp-Key Employees 37
MannKind Corp-Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Strategy And Business Planning 39
Sep 05, 2018: MannKind and United Therapeutics to advance dry powder treprostinil 39
Financial Announcements 40
Nov 01, 2018: MannKind reports 2018 third quarter financial results 40
Aug 02, 2018: MannKind Reports 2018 Second Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET 42
May 09, 2018: MannKind Reports 2018 First Quarter Financial Results 44
Feb 27, 2018: MannKind Reports 2017 Fourth Quarter and Full Year Financial Results 45
Nov 07, 2017: MannKind Reports 2017 Third Quarter Financial Results 47
Aug 07, 2017: MannKind Reports 2017 Second Quarter Financial Results 49
May 10, 2017: MannKind Reports 2017 First Quarter Financial Results 51
Mar 16, 2017: MannKind Reports 2016 Fourth Quarter and Full Year Financial Results 52
Corporate Communications 53
Jun 25, 2018: MannKind Set to Join Russell 3000 Index 53
Feb 06, 2018: MannKind Names David Kendall As Chief Medical Officer 54
Jul 17, 2017: Steven Binder Joins MannKind as Chief Financial Officer 55
Jul 12, 2017: Patrick McCauley Joins MannKind as Chief Commercial Officer 56
Jan 04, 2017: MannKind Announces Key Addition to Its Executive Management Ranks 57
Product News 58
08/17/2018: NUI Galway finds new treatment strategy for breast cancer relapse 58
Mar 08, 2017: MannKind and Charles Mattocks Announce "REVERSED"-America's First Docu-Series Tackling Diabetes 59
02/01/2017: MannKind Announces Launch of New Titration Pack and Field Force Expansion to Accelerate Afrezza Growth 60
Other Significant Developments 61
Jan 09, 2017: MannKind Receives USD 30.6 Million From Sanofi 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62
List of Figure
List of Figures
MannKind Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MannKind Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
MannKind Corp, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
MannKind Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MannKind Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MannKind Corp, Deals By Therapy Area, 2012 to YTD 2018 9
MannKind Corp, Medical Devices Deals, 2012 to YTD 2018 10
MannKind Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
MannKind Enters into Distribution Agreement with Tanner Pharma 12
MannKind to Enter into Marketing and Distribution Agreement with Cipla 13
MannKind and Biomm Enter into Distribution Agreement 14
MannKind Partners with JDRF 15
United Therapeutics Enters into Licensing Agreement with MannKind 16
Receptor Life Sciences Enters into Licensing Agreement with MannKind 17
Colby Enters Into Licensing Agreement With MannKind For Cancer Immunotherapy Products 18
MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton's Tyrosine Kinase Inhibitors 20
MannKind Raises USD28 Million in Private Placement of Shares 21
Mannkind to Raise USD61 Million in Private Placement of Shares 23
MannKind Plans to Raise Funds through Private Placement of Shares upon Exercise of Warrants 25
MannKind Raises USD36.2 Million in Private Placement of Shares 26
Mannkind Raises USD50 Million in Private Placment of Shares 27
MannKind Announces Public Offering Of Common Stock For USD 50 Million 29
MannKind Completes Public Offering Of Common Stock And Warrants For USD 92 Million 30
MannKind Completes Public Offering Of Units For USD 86 Million 32
MannKind Completes First Tranche Of Private Placement Of Notes For USD 40 Million 34
MannKind Corp, Key Competitors 36
MannKind Corp, Key Employees 37
MannKind Corp, Other Locations 38
MannKind Corp, Subsidiaries 38
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.